525 B Street, Suite 2200
San Diego, CA 92101
Robert (Bob) Ramos has over 20 years of combined Life Sciences IP experience in both private practice and the biotechnology industry related to worldwide patent and trademark acquisition and strategic counseling. Bob has assisted venture-backed startups, mid-sized companies, basic research Institutes, as well as large biopharmaceutical companies in need of extensive portfolio management in the biotechnology arts, including molecular biology, antibodies/peptibodies, protein therapeutics, cancer therapies, gene therapy, cellular immunotherapy, and nucleic acids; as well as next generation sequencing and modern genomics, including microfluidics, microarrays, bioinformatic and pharmacogenomic analysis for personalized medicine and companion diagnostics.
Bob has extensive Biopharma industry experience where he participated in hundreds of detailed global patent strategy decisions for high value IP assets. His practice includes preparing and prosecuting U.S. and foreign patent applications, patent landscape analysis, opinion work, including patentability, non-infringement, invalidity and freedom-to-operate opinions. His practice also includes due diligence analysis in connection with venture capital, public and private financing, mergers & acquisitions; as well as litigation support, post-Grant Oppositions, and worldwide Trademark procurement and enforcement strategy. As part of an extensive patent strategy, Bob co-managed the expedited generation of a lead recombinant protein and its accelerated pre-clinical development to acceptance for First-In-Human clinical trials.
He conducted his graduate work in biology at UCSD, with an emphasis on molecular genetics, where he constructed genetically engineered viruses for potential use in gene therapy. Prior to joining the firm, Bob practiced at Amgen for over 10 years, where he was the lead IP Attorney for 2 commercial and 2 Phase I biologics. Bob also managed the worldwide procurement and enforcement strategy for a trademark portfolio comprising hundreds of registered trademarks protecting numerous pharmaceutical products.
Bob’s experience in molecular biology, law and business is a unique combination among lawyers, and he has a keen understanding of the unique IP legal and business challenges currently faced by many biotechnology companies.
"In addition to being an outstanding, highly creative and winning patent counsel, Procopio attorney Bob Ramos, goes extra miles for his client by leveraging his long-term reputation and relationships for his clients - he is well connected in the Pharma world and freely makes important and key introductions to help his clients advance strategic partnering connections, and gain access to leading scientists and business leaders."
-- Larry G Stambaugh, Chairman of the Board, Molecular Assemblies, Inc. and Life Director – BIOCOM Board of Directors
“I have worked with many firms and several attorneys for my multiple ventures. I’m yet to find any firm that even comes close to Procopio in terms of professionalism, broad scope and expertise as well as familiarity with the challenges of startups. In Procopio, I’m very fortunate to have been working with Robert Ramos for over 3 years, who is one of the best attorneys in the nation with a deep understanding of the life sciences. I’m always impressed with his ability to grasp concepts and ideas quickly and build strong patents around them while forming powerful strategies to build a versatile patent portfolio that leads to a productive licensing strategy. Moreover, through his great network with the industry, he generously provides productive connections and works like an actual partner of the company more than an advisor. These points have given me confidence to consolidate all my ventures under Procopio and I am looking forward to working with Bob Ramos and his team for years to come.“
-- Inanc Ortac, Founder, CSO of DevaCell; Founder, CSO of Sarmal; Founder, CEO, CSO of Innovasion Labs PINC; and recipient of the 2020 Biocom California Life Science Catalyst Award
- Board of Directors, Biocom, 2019-to present
- State Bar of California
- American Intellectual Property Law Association
- San Diego Intellectual Property Law Association
- San Diego Venture Group
- JD, University of San Diego School of Law
- MS, (Biology/Molecular Genetics) University of California, San Diego
- BS, (Molecular Biology) University of California, San Diego
- Jared Whitlock. “Biocom Adds 3 Board Members,” San Diego Business Journal, August 26, 2019.
- “Biocom Appoints Additional Members to Board of Directors from Bayer, KPMG and Procopio,” Biocom, August 26, 2019.”
- Bradley Fikes. “ Life Technologies Wins U.S. Supreme Court Patent Case,” (C1, continued on C4) The San Diego Union-Tribune. February 23, 2017.
- Randy Frisch. "Attorney Brings Life Science Expertise to New Role at Procopio," San Diego Business Journal, August 1, 2016
- Presenter. “Managing 3rd Party IP and Freedom-To-Operate in Drug Development,” The 17th Annual San Diego BioPharma Conference, San Diego, Ca, June 9, 2018.
- Co-presenter. “The 21st SABPA Entrepreneur Symposium — Licensing of IP & Tech Transfer in Biotech Arena,” San Diego, Ca, April 12, 2018.
- Moderator. “Biosimilars IP Litigation: Where We've Been and Where We're Heading,” BIO International Convention, San Diego, CA, June 21, 2017.
- Panelist - "Don't Fear the Walking Dead: Patent Eligibility Survival Strategies for Biotech and Life Sciences Patents," Licensing Executives Society, Inc. - Silicon Valley Chapter, October 19, 2016.
- Panelist - “WHERE TO FILE: A Framework For Pharmaceutical and Biotechnology Companies To Develop An International Patent Filing Strategy,” Thomas Jefferson School of Law International Symposium, San Diego, April 2014.
- Co-author. "Obtenga de manera rápida patentes relacionadas con el COVID-19 . . . ¡Sin costo adicional!," August 5, 2020.
- Co-author. "Obtain COVID-19-Related Patents Fast... At No Additional Cost!," May 11, 2020.
- "USPTO Further Extends Certain Patent Filing Deadlines," May 4, 2020.
- "USPTO Extends Certain Patent Filing Deadlines," April 8, 2020.
- "Cares Act Provides USPTO Discretion To Extend Certain Patent and Trademark Filing Deadlines," March 30, 2020.
- “Millennium Case May Strengthen IP Portfolios of Pharma Companies,” July 21, 2017.
DISCLAIMER: Testimonials or endorsements do not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter.